Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.
Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. Villar-Prados A, et al. Among authors: ma s. Mol Cancer Ther. 2019 Feb;18(2):421-436. doi: 10.1158/1535-7163.MCT-18-0365. Epub 2018 Nov 12. Mol Cancer Ther. 2019. PMID: 30420565 Free PMC article.
GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.
Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. Ma S, et al. Mol Cancer Ther. 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29. Mol Cancer Ther. 2019. PMID: 30926640 Free PMC article.
Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.
Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Kim MS, et al. Among authors: ma s. Mol Cancer Ther. 2020 Nov;19(11):2396-2406. doi: 10.1158/1535-7163.MCT-20-0030. Epub 2020 Sep 17. Mol Cancer Ther. 2020. PMID: 32943548 Free PMC article.
Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.
Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. Handley KF, et al. Among authors: ma s. Mol Cancer Ther. 2021 Dec;20(12):2352-2361. doi: 10.1158/1535-7163.MCT-21-0370. Epub 2021 Sep 28. Mol Cancer Ther. 2021. PMID: 34583979 Free PMC article.
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.
Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Dalton HJ, et al. Among authors: ma s. Clin Cancer Res. 2017 Nov 15;23(22):7034-7046. doi: 10.1158/1078-0432.CCR-17-0647. Epub 2017 Aug 29. Clin Cancer Res. 2017. PMID: 28855350 Free PMC article.
Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.
Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK. Chen X, et al. Among authors: ma s. Oncogene. 2019 Aug;38(33):6095-6108. doi: 10.1038/s41388-019-0862-y. Epub 2019 Jul 9. Oncogene. 2019. PMID: 31289363 Free PMC article.
Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer.
Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. Lara OD, et al. Among authors: ma s. Oncotarget. 2020 Jul 21;11(29):2819-2833. doi: 10.18632/oncotarget.27667. eCollection 2020 Jul 21. Oncotarget. 2020. PMID: 32754300 Free PMC article.
MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
Wu Y, Huang J, Ivan C, Sun Y, Ma S, Mangala LS, Fellman BM, Urbauer DL, Jennings NB, Ram P, Coleman RL, Hu W, Sood AK. Wu Y, et al. Among authors: ma s. Gynecol Oncol. 2021 Oct;163(1):181-190. doi: 10.1016/j.ygyno.2021.08.003. Epub 2021 Aug 11. Gynecol Oncol. 2021. PMID: 34391578 Free PMC article.
CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance.
Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AK. Ma S, et al. Cell Rep. 2021 Aug 17;36(7):109549. doi: 10.1016/j.celrep.2021.109549. Cell Rep. 2021. PMID: 34407412 Free PMC article.
14,282 results
You have reached the last available page of results. Please see the User Guide for more information.